Staging, prognostic factors, and therapy of localized rectal cancer.
Many recent developments have taken place in the management of rectal cancer. Appropriate staging plays an increasingly important role in rectal cancer, because many treatment decisions must be based on preoperative staging. Also critical is the role of prognostic factors such as the pathologic T (tumor) and N (nodal) classification, circumferential resection margin, and response to preoperative therapy. For stage II and III rectal cancer, preoperative chemo-radiation and radiotherapy have been accepted widely as a standard of care. The German Rectal Cancer Trial demonstrated the superiority of preoperative chemoradiation over postoperative chemoradiation, whereas the trials from the European Organisation for Research and Treatment of Cancer and Fédération Francophone de Cancérologie Digestive showed the benefits of preoperative chemoradiation over preoperative long-course radiotherapy. Multiple randomized trials also have established the role of hypofractionated or short-course radiotherapy. For stage I rectal cancer, local excision is being used increasingly, but recent studies show the need for caution with the use of this technique. This article reviews recent studies on staging, prognostic factors, and therapy of localized rectal cancer.